Although histopathology and imaging remain the gold standard methods for diagnosis, our study substantiates that HE4 would be a novel potential biomarker for diagnosing and predicting early‐stage lung cancer, which would offer a novel avenue for therapeutic targeting and present a strategic approach to improve the prognosis of lung cancer patients. This evidence concerns the gene WFDC2 and lung cancer.